Promoting axon regeneration by overexpression of Nrf2 and use of edaravone

By activating Nrf2, edalavone induced Nrf2 activation, the problem of axon no regeneration after central nervous system injury was solved, significantly promoted axon regeneration and neuronal survival, and provided safe and effective functional recovery treatment.

CN118903114APending Publication Date: 2024-11-08THE HONG KONG UNIV OF SCI & TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410553952.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-07
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The axon does not spontaneously regenerate after central nervous system damage in adult mammals, resulting in persistent dysfunction. The existing treatment methods are limited in effect and lack safe and effective functional recovery treatment.

Method used

By activating the nuclear factor erythrocyte 2-related factor 2 (Nrf2), edalavone is used to induce Nrf2 activation, reducing the production of reactive oxygen species (ROS), and promoting axonal regeneration and neuronal survival after central nervous system damage.

Benefits of technology

Overexpression of Nrf2 significantly promotes axonal regeneration and retinal ganglion cell survival after optic nerve injury. Edaravone, as an FDA-approved antioxidant, effectively promotes axon growth and neuronal protection, providing an alternative method for clinical trials. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903114A_ABST
    Figure CN118903114A_ABST
Patent Text Reader

Abstract

The present application relates to a method of promoting axonal regeneration in subjects, including subjects with central nervous system (CNS) impairment, by Nrf2 activation induced by edaravone.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application Serial No. filed on May 8, 2023. 63 / 500,622, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present invention relates to the field of treatment of nervous system injury, and more particularly to a new method for axon regeneration. Background Art

[0003] Axons do not spontaneously regenerate after injury in the adult mammalian central nervous system. This phenomenon leads to persistent dysfunction of the nervous system after injury and limits the development of reparative treatments for central nervous system (CNS) injuries.

[0004] Exogenous factors and endogenous factors work together to hinder axon regeneration after CNS injury. CNS injury triggers reactive astrocyte proliferation and chondroitin sulfate proteoglycan (CSPG) secretion at the damaged site, and promotes glial scar formation (see Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 5 (2): 146-56 (2004); EJ Bradbury and ER Burnside. Moving beyond the glial scar for spinal cord repair. Nat. Commun., vol. 10, no.1, Art.no.1(2019)). Myelin-related molecules (such as Nogo and MAG) It is another major component that promotes the formation of an inhibitory environment for axonal regeneration (see Mukhopadhyay et al., A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron. 13(3):757-67 (1994); Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neuritegrowth inhibitors. Nature. 18;343(6255):269-72(1990)).

[0005] The inhibitory effects of these exogenous inhibitors have been studied by pharmacological or genetically mediated elimination. Previous studies have shown that a variety of neuronal endogenous pathways can be targets for developing therapeutic strategies (see He, Z. & Jin, Y. Intrinsic control of axon regeneration. Neuron 90, 437-451 (2016)). However, clinically applicable drugs targeting these pathways have only shown a slight effect on axon regeneration, which hinders the application of these drugs in clinical treatment (see Lee et al., Sustained delivery of thermostatically enhanced chABC enhances axonal sprouting and functional recovery after spinal cord injury. Proc Natl Acad Sci USA. 23;107(8):3340-5(2010); JK Lee et al., Assessing Spinal AxonRegeneration and Sprouting in Nogo-,MAG-,and OMgp-Deficient Mice. Neuron, vol.66, no.5, pp.663-670 (2010); JK Lee et al., Reassessment of Corticospinal Tract Regeneration in Nogo-Deficient Mice.Neuron, vol.38,no.2,pp.213-224(2003)).

[0006] Several endogenous factors related to axon regeneration have been found, such as PTEN (see Park et al., Promoting axon regeneration in the adult CNS by modulation of the PTEN / mTOR pathway. Science, vol. 322, no. 5903, pp. 963-966 (2008)), Socs3 (see PD Smith et al., SOCS3 deletion promotes optic nerve regeneration in vivo. Neuron, vol. 64, no. 5, pp.617-623 (2009)), B-RAF (see KJO'Donovan et al., B-RAF kinase drives developmental axon growth and promotes axon regeneration in the injured mature CNS. J. Exp. Med., vol. 211, no. 5, pp. 801-814 (2014)), c-Myc (see reference S. Belin et al., Injury-induced decline of intrinsic regenerative ability revealed by quantitative proteomics. Neuron, vol. 86, no. 4, pp. 1000-1014 (2015)) and Lin28 (See Wang et al., Lin28 Signaling Supports Mammalian PNS and CNS Axon Regeneration. Cell Rep., vol. 24, no. 10, pp. 2540-2552. e6 (2018)). However, there is still a lack of highly effective inhibitors or activators targeting these intrinsic factors. In addition, most of these intrinsic factors are tumor suppressor genes or oncogenes, and The deletion or activation of these genes can disrupt cellular homeostasis and impair neuronal function (see J.D. Buckbaum et al., Mutation Screening of the PTEN Gene in Patients With Autism Spectrum Disorders and Macrocephaly. Am. J. Med.Genet., vol.144B, no.4, pp.484-491 (2007)) or induce tumor formation (see M.Milella et al., PTEN: Multiple Functions in Human Malignant Tumors. Front. Oncol., vol.5 (2015); M.Gabay et al., MYC Activation Is a Hallmark of Cancer Initiation and Maintenance. Cold Spring Harb. Perspect. Med., vol. 4, no. 6 (2014); J. Balzeau et al., The LIN28 / let-7 Pathway in Cancer,” Front.Genet.,vol.8,Mar.2017,doi: 10.3389 / fgene.2017.00031). These side effects strongly hinder the clinical application of the discovered endogenous factors. Currently, existing treatments are still difficult to meet the needs of clinical trials. Therefore, there is no clinically applicable drug for functional recovery treatment after CNS injury. Therefore, there is a need for safe and effective functional recovery treatment after CNS injury. Summary of the invention

[0007] The present application provides a method for using nuclear factor erythroid 2-related factor 2 (Nrf2) Methods of activating and thereby promoting axonal regeneration in a subject with central nervous system (CNS) injury.

[0008] In a preferred embodiment, Nrf2 activation is induced by edaravone (5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one).

[0009] In some embodiments, a therapeutically effective amount of Edaravone is administered to the subject.

[0010] In a further embodiment, the present application is a method for treating a subject with central nervous system (CNS) damage through Nrf2 activation, the method comprising administering a therapeutically effective amount of edaravone to a subject in need thereof, wherein Nrf2 activation is induced by edaravone.

[0011] In preferred embodiments, administration of edaravone to a subject upregulates Nrf2, which binds to the antioxidant response element (AR) site, and upregulation of Nrf2 reduces the generation of reactive oxygen species (ROS).

[0012] In a more preferred embodiment, overexpression of Nrf2 significantly promotes axonal regeneration after optic nerve injury.

[0013] In some embodiments, edaravone is administered topically by intravitreal injection, intracranial injection, intradiscal injection, or administered by intravenous injection, intraperitoneal injection to a subject suffering from CNS damage, wherein administration of edaravone enhances neuronal survival and promotes axonal growth in the subject.

[0014] In some embodiments, the subject is a mammal, preferably, the mammal is a primate, and more preferably, the primate is a human.

[0015] In some embodiments, the CNS injury may be spinal cord injury, traumatic brain injury, optic neuropathy, stroke, or glaucoma.

[0016] In a preferred embodiment, edaravone is administered to a subject at a dose of about 0.1 mg / kg to about 100 mg / kg, and more preferably at a dose of about 5 mg / kg to about 80 mg / kg.

[0017] In a more preferred embodiment, edaravone is administered to the subject at a dose of 60 mg / day via a 60 minute IV infusion.

[0018] In a preferred embodiment, edaravone is administered in a composition at a concentration of about 0.1 μg / mL to about 10 mg / mL.

[0019] In other embodiments, Nrf2 activation may be induced by adeno-associated virus (AAV)-mediated overexpression of Nrf2 or may be induced by an Nrf2 activator. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1A to Figure 1B It was shown that Nrf2 overexpression promoted optic nerve regeneration. Figure 1A ) Optic nerve sections of WT mice 2 weeks after injury. Intravitreal injection with either AAV2-GFP control or AAV2-Nrf2. Axons were labeled by CTB-FITC. Scale bar: 200 μm. ( Figure 1B ) Figure 1A Quantification of regenerating axons at the indicated distances from the injured site. **p ≤ 0.01. ANOVA followed by Bonferroni test, n = 4 mice to 5 mice.

[0021] FIG. 2A to FIG. 2B Nrf2 overexpression was shown to enhance retinal ganglion cell (RGC) survival after optic nerve injury. Figure 2A ) Retinal flat mounts of wild-type mice 2 weeks post-injury using whole-tissue Tuj1 staining. Vitreous was injected with either AAV2-GFP control or AAV2-Nrf2. Scale bar: 50 μm. ( Figure 2B ) Figure 2A Middle RGC Quantification of survival. **p≤0.01. Student's t-test, n=4 to 5 mice.

[0022] FIG. 3A to FIG. 3B Edaravone was shown to promote axonal elongation in DRG replating cultures. Figure 3A ) Representative images of re-plated DRG neurons treated with DMSO vehicle control and the concentration of edaravone is indicated. Scale bar: 400 μm. ( Figure 3B ) Quantification of the longest neuron length for the tested concentrations of edaravone. Points represent the measurement results for each neuron.

[0023] FIG. 4A to FIG. 4B Daily treatment with edaravone was shown to increase RGC survival after optic nerve injury. Figure 4A ) Wild-type (WT) 2 weeks after injury using whole-tissue Tuj1 staining Retinal flat mounts of mice. Mice received vehicle or different doses of edaravone intraperitoneally (IP) injection.( Figure 4B ) Figure 4A Quantification of RGC survival in . **p≤0.01.

[0024] Figure 5 Summary of factors for converting doses between animals and humans. DETAILED DESCRIPTION

[0025] The selected definition

[0026] As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. In addition, the terms "including" and "includes" are used in the detailed description and / or claims. When the terms "having, has," "with," or variations thereof, such terms are intended to be inclusive in a manner similar to the term "comprising." The transitional terms / phrases (and any grammatical variations thereof) "comprising, comprises, comprise," "consisting essentially of, consists essentially of," and "consisting, consists" may be used interchangeably.

[0027] The phrases "consisting essentially of, consists essentially of" mean that the claim includes embodiments containing the specified materials or steps as well as those that do not materially affect the basic and novel characteristics of the claim.

[0028] The term "about" means within an acceptable error range of a particular value determined by a person of ordinary skill in the art, which depends in part on how the value is measured, i.e., the limitations of the measurement system. In the case where the term "about" is used with respect to the amount of an ingredient contained in a composition, these compositions contain a specified amount of the ingredient, and the variation (error range) of the specified amount is about 0% to 10% (X ± 10%) above and below its value. In other cases, the variation (error range) provided by the term "about" is 0% to 10% (X ± 10%) above and below a given value. Obviously, this variation represents a range of up to 10% above or below a given value, for example, X ± 1%, X ± 2%, X ± 3%, X ± 4%, X ± 5%, X ± 6%, X ± 7%, X ± 8%, X ± 9%, or X ± 10%.

[0029] In the present disclosure, scope is stated in shorthand form to avoid having to state in detail and describe each value in the scope. Where appropriate, any suitable value in the range can be selected as the upper limit, lower limit or end value of the range. For example, the range of 0.1 to 1.0 represents the end value is 0.1 and 1.0, and the median is 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and all intermediate ranges included in 0.1 to 1.0, such as 0.2 to 0.5, 0.2 to 0.8 and 0.7 to 1.0 etc. It is conceivable that there are at least two significant figures in a range, for example, the range of 5 to 10 represents the whole values ​​between 5.0 and 10.0 and between 5.00 and 10.00, including the end value. When using scope in this article, the combination and sub-combination (for example, the sub-range in the disclosed range) of the scope and the specific embodiments thereof are clearly included.

[0030] As used herein, "subject," "host," or "organism" refers to any member of the phylum Chordata, more preferably any member of the subphylum Vertebrata, or most preferably any member of the class Mammalia, including but not limited to humans and other primates, including non-human primates such as rhesus macaques, chimpanzees and other monkeys and ape species; livestock such as cattle, sheep, pigs, goats, and horses; domesticated mammals such as dogs and cats; laboratory animals, including rabbits, mice, rats, and guinea pigs. The term does not denote a particular age or sex. Thus, it is intended that adult, juvenile, and newborn individuals, as well as male and female subjects, are covered. In some embodiments, the host tissue is derived from the subject. In some embodiments, the subject is a non-human subject.

[0031] As used herein, the terms "therapeutically effective amount," "therapeutically effective dose," "effective amount," and "effective dose" are used to refer to the amount or dose of a compound or composition that, when administered to a subject, is capable of treating, preventing, or ameliorating a condition, disease, or disorder in a subject. That is, the amount is "therapeutically effective" when administered to a subject. The actual amount will vary depending on a number of factors, including, but not limited to, the specific condition, disease, or disorder being treated, prevented, or ameliorated; the severity of the condition; the patient's weight, height, age, and health; and the route of administration.

[0032] As used herein, the term "treat" means to eradicate; reduce; ameliorate; eliminate; relieve; lessen symptoms or delay the onset of symptoms; slow the rate of deterioration or decline; make the endpoint of deterioration less debilitating; and / or improve the physical or mental health of the subject, or to reverse the signs or symptoms of a health condition, disease or disorder to any extent, including but not requiring a complete cure of the condition, disease or disorder. Treatment can cure, ameliorate or partially ameliorate a condition. "Treatment" can also include improving or enhancing a condition or feature, for example, bringing the function of a particular system in the body to a higher state of health or homeostasis.

[0033] As used herein, "preventing" a health condition, disease, or disorder means avoiding, delaying, preventing, or minimizing the onset of specific signs or symptoms of that condition, disease, or disorder. Prevention can be complete or thorough, but this is not required; that is, signs or symptoms may continue to develop at a later time. Prevention can include reducing the severity of the onset of such a condition, disease, or disorder, and / or inhibiting the progression of a condition, disease, or disorder to a more serious condition, disease, or disorder.

[0034] In some embodiments of the present application, the method comprises administering multiple doses of the compound of the present application. The method may comprise administering 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100 or more therapeutically effective doses of a composition comprising a compound of the present application as described herein. In some embodiments, within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, 21 days, 30 days, 2 months, 3 months, 6 months, 9 months, 1 year, 1.5 years, 2 years, 2.5 years, The dosage is administered over a period of 5 years or more than 10 years. The frequency and duration of administration of the multiple dose composition is for example to prevent or treat endothelial dysfunction. In addition, treating a subject with a therapeutically effective amount of the compound of the present application may include a single treatment or may include a series of treatments. It will also be recognized that the effective dose of the compound used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result in test results of endothelial dysfunction, such as magnetic resonance imaging or positron emission tomography, and make these results apparent. In some embodiments of the present application, the method includes administering the compound multiple times a day, including but not limited to 2 times a day, 3 times a day, and 4 times a day.

[0035] As used herein, an "isolated" or "purified" compound is substantially free of other compounds. In certain embodiments, the purified compound is at least 60% by weight (dry weight) of the target compound. Preferably, the preparation is at least 75% by weight of the target compound, more preferably at least 90% by weight, and most preferably at least 99% by weight. For example, a purified compound is at least 90%, 91%, 92%, 93%, 94%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 1 93 wt%, 94 wt%, 95 wt%, 98 wt%, 99 wt% or 100 wt%. % of compound. Purity is determined by any appropriate standard method, for example by column chromatography, thin layer chromatography or high performance liquid chromatography (HPLC) analysis.

[0036] By "reduced" is meant a negative change of at least 1%, 5%, 10%, 25%, 50%, 75% or 100%.

[0037] By "increase" is meant a positive change of at least 1%, 5%, 10%, 25%, 50%, 75% or 100%.

[0038] As used herein, "drug" refers to a chemical compound manufactured for use as a pharmaceutical material and / or therapeutic drug.

[0039] Any composition or method provided herein can be combined with one or more of any other compositions and methods provided herein.

[0040] Other features and advantages of the present application will be apparent from the following description of preferred embodiments of the application and from the claims.

[0041] All references cited herein are incorporated by reference in their entirety.

[0042] The present application relates to a novel method for promoting axonal regeneration in subjects with CNS injury by activating the therapeutic target nuclear factor erythroid 2-related factor 2 (Nrf2). Nrf2 overexpression significantly promotes axonal regeneration after CNS nerve injury. Edaravone is an FDA-approved antioxidant drug and an effective Nfr2 activator that promotes axonal growth.

[0043] Traumatic injury to the CNS leads to permanent dysfunction of the motor and sensory systems, mainly due to the lack of axon regeneration, which leads to neuronal loss. Axons do not spontaneously regenerate after CNS injury in adult mammals, which leads to persistent dysfunction of the nervous system after injury and limits the development of repair treatments for CNS injuries. Although previous studies have shown that multiple neuronal endogenous pathways can be targets for the development of therapeutic strategies (see He, Z. & Jin, Y. Intrinsic control of axon regeneration. Neuron 90, 437-451(2016)), but there is still a lack of clinically applicable drugs targeting these pathways.

[0044] We identified a new therapeutic target, nuclear factor erythroid 2-related factor 2 (Nrf2), which significantly promoted axon regeneration after optic nerve injury when overexpressed. In addition, Nrf2 overexpression significantly enhanced retinal ganglion cell (RGC) survival after injury. In addition, screening of Nrf2 activators identified the FDA-approved antioxidant drug edaravone, which exhibited axon growth-promoting and neuron-protective effects on nerve injury.

[0045] Neurons undergo multiple cellular and signaling events after injury, such as endoplasmic reticulum (ER) Stress (see Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 110: 1389-1398 (2002)), mitochondrial dysfunction (see Zhao et al., Mitochondrial dysfunction in neural injury. Frontiers in Neuroscience, vol. 13 (2019)), increased reactive oxygen species (ROS) (see Ryan et al., Oxidative stress in the brain and retina after traumatic injury. Front. Neurosci., Volume 17 (2023)), changes in anabolic and decomposition pathways (see Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci.5(2):146-56 (2004)). In traumatic injury (see Ryan et al., Oxidative stress in the brain and retina after traumatic injury. Front. Neurosci., Volume 17 (2023)) and neurodegenerative diseases (see reference DA Drechsel and M. Patel. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radical Biology & Medicine, vol. 44, no. 11, pp. 1873-1886 (2008)). As a product of cellular oxidative metabolism, ROS plays a vital role in regulating cell signaling, cell proliferation, cell differentiation, cell survival and inflammation (see Ray, P. D.,Huang,BW&Tsuji,Y.Reactive oxygen species(ROS) homeostasis and redox regulation in cellular signaling.CellSignal.24, 981-990 (2012). Depending on the physiological or pathological conditions involved, ROS can show protective or deleterious effects. In the case of traumatic injury, excessive production of ROS by mitochondria leads to changes in many macromolecules and impairs neuronal survival and functional recovery. However, capturing and clearing ROS can improve the progression of the disease.

[0046] Nrf2 is a transcription factor that binds to the antioxidant response element (ARE) site in the cell nucleus after activation and regulates the expression of many genes with antioxidant effects (see Oh, YS & Jun, H.-S. Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling. Int. J. Mol. Sci. 19, 26 (2018)). Edaravone is an FDA-approved antioxidant drug for the treatment of the neurodegenerative disease amyotrophic lateral sclerosis (ALS) (see US FDA: US Label Edaravone, May 2018). 2017). We found that edaravone treatment reduced ROS generation by upregulating the antioxidant gene Nrf2 (see Hassanein et al., Edaravone and Acetovanillone Upregulate Nrf2 and PI3K / Akt / mTOR Signaling and Prevent Cyclophosphamide Cardiotoxicity in Rats. Drug Des. Dev. Ther. 14, 5275-5288 (2020); Dang et al., Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1 / Nrf2 / HO-1 / Gpx4 pathway. Journal of Neuroinflammation, vol. 19, no. 1, p. 41 (2022)). We found that overexpression of Nrf2 significantly promoted axon regeneration and enhanced RGC survival after optic nerve injury. In addition, by screening Nrf2 activators, we found that the FDA-approved drug edaravone can promote axon growth.

[0047] In some embodiments, Nrf2 is effective in significantly promoting axonal regeneration after CNS injury and providing neuronal protection after CNS injury.

[0048] In a preferred embodiment, edaravone promotes DRG axon outgrowth after replating.

[0049] In a more preferred embodiment, edaravone can cross the blood-brain barrier and target central nervous system neurons.

[0050] In some embodiments, edaravone reduces ROS and promotes axonal growth when compared to genetic overexpression of Nrf2, thus providing an alternative approach for clinical trials.

[0051] In a further embodiment, Nrf2 activation can be induced by adeno-associated virus (AAV)-mediated overexpression.

[0052] In some embodiments, edaravone may be administered in a composition at a concentration of about 0.1 μg / mL to about 10 mg / mL.

[0053] In some embodiments, the dosage may be about 0.1 mg / kg to about 100 mg / kg, about 0.25 Edaravone is administered in a dose of about 100 mg / kg to about 75 mg / kg or about 50 mg / kg.

[0054] In a preferred embodiment, edaravone may be administered at a dose of about 0.25 mg / kg to about 75 mg / kg.

[0055] In a preferred embodiment, edaravone is administered to a subject at a dose of about 0.1 mg / kg to about 100 mg / kg, and more preferably at a dose of about 5 mg / kg to about 80 mg / kg.

[0056] In a more preferred embodiment, edaravone is administered to the subject at a dose of 60 mg / day via a 60 minute IV infusion.

[0057] Edaravone can be added to the composition in an amount of about 0.0001 weight % (wt%) to about 5 weight % (wt%), preferably about 0.01 weight % to about 0.5 weight %, and most preferably about 0.1 weight %. In another embodiment, Edaravone can be combined with an acceptable carrier and / or excipient, wherein Edaravone can be present in an amount of about 0.0001 volume % to about 5 volume %, preferably about 0.01 volume % to about 0.5 volume %, more preferably about 0.05 volume % to about 0.25 volume %, or most preferably about 0.1 volume %.

[0058] In some embodiments, edaravone can be administered locally by intravitreal injection, intracranial injection, intradiscal injection, or administered intravenously or intraperitoneally.

[0059] In some embodiments, edaravone may be administered to a subject by intravitreal injection at a dose of about 0.5 mM to about 10 mM.

[0060] In some embodiments, the edaravone composition can be administered locally by intravitreal injection, intracranial injection, intradiscal injection, or administered intravenously or intraperitoneally.

[0061] The composition of the present application may further contain additives commonly used in pharmaceutical preparations.

[0062] In certain embodiments, the composition of the present application of a therapeutically effective amount can be administered intraperitoneally or by a sustained release system, and the sustained release system is, for example, a semi-permeable matrix of a solid hydrophobic polymer comprising a compound of the present application. Administration can also be by other carriers or carriers, such as patches, micelles, liposomes, vesicles, implants (such as micro-implants), synthetic polymers, microspheres, nanoparticles, etc. In certain embodiments, nanoparticles can be used to administer the composition so that the composition passes through the skin.

[0063] In certain embodiments, the composition of the present application can be formulated for parenteral administration, intravenous administration, intraperitoneal administration or continuous infusion, for example, by injection such as bolus injection. In addition, the composition can be present in an ampoule, prefilled syringe and small volume infusion with or without preservative, or in a multidose container in a unit dose form. The composition can be in the form of a suspension, solution or emulsion in an oily or aqueous vehicle. The composition can also include formulation agents, such as suspending agents, stabilizers and / or dispersants. In a further embodiment, the active ingredient according to the composition of the present application can be in powder form before use, which is obtained by aseptic separation of sterile solids or by freeze drying a solution composed of a suitable vehicle such as sterile pyrogen-free water.

[0064] No matter which administration route is chosen, the composition can be formulated into a pharmaceutically acceptable dosage form by conventional methods known to those skilled in the art. The composition can be formulated by analogy with other drugs to be administered in any convenient way for use in human or veterinary medicine.

[0065] The composition may further comprise one or more pharmaceutically acceptable carriers and / or excipients, and the composition may be formulated into, for example, a semisolid or liquid form of preparation, such as a solution or injection.

[0066] Preparations can be conveniently presented in unit dosage form and can be prepared by any method well-known in the field of pharmaceutics. The amount of the compound that can be combined with a carrier material to produce a single dosage form will vary according to the subject being treated, a specific mode of administration. The amount of the active ingredient that can be combined with a carrier material to produce a single dosage form is generally the amount of the compound that will produce a therapeutic effect. Usually, within a hundred percent range, the amount ranges from about 1% by weight to about 99% by weight of active ingredient, preferably from about 5% by weight to about 70% by weight, most preferably from about 10% by weight to about 30% by weight of active ingredient.

[0067] As used herein, the term "pharmaceutically acceptable" means compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof.

[0068] Carriers and / or excipients according to the present application may include any and all solvents, diluents, buffers (e.g., such as neutral buffered saline, phosphate buffered saline or optionally tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), acetate or phosphate buffers), oil-in-water or water-in-oil emulsions, aqueous compositions with or without organic co-solvents suitable for, e.g., IV use, solubilizers (e.g., polysorbate 65, polysorbate 80), colloids, dispersion media, carriers, fillers, chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA) or glutathione), amino acids (e.g., glycine), proteins, disintegrants, binders, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, fragrances, thickeners (e.g., carbomer, gelatin or sodium alginate), coatings, preservatives (e.g., thimerosal, benzyl alcohol, polyquaternium salts), antioxidants (e.g., ascorbic acid, sodium pyrosulfite), tension control agents, absorption delay agents, adjuvants, fillers (e.g., lactose, mannitol), etc. The use of carriers and / or excipients in the field of medicines and supplements is well known. In addition to any conventional media or agents that are incompatible with the target health-promoting substance or composition, it is contemplated that a carrier or excipient may be used in the composition of the present application.

[0069] In a preferred embodiment, at least one dose of composition is repeatedly applied at least every day in about 7 weeks or longer. In certain embodiments, at least one dose of composition is repeatedly applied at least for about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 52 weeks or longer. In a preferred embodiment, at least one dose of composition is repeatedly applied every about 2 days to about 5 days, and it lasts for about 2 weeks to about 10 weeks.

[0070] Data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans. For example, an effective dose obtained in one animal species can be extrapolated to effective doses in other animals, including humans. Figure 5 The dose factors for human equivalent doses (HED) based on body surface area of ​​other species are reported in the table below. The dose of any supplement, or alternative dose of any component thereof, is preferably within the range that includes the ED 50 The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For a compound or combination of compounds, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve an IC determined in cell culture. 50 The invention also provides a method for determining the circulating plasma concentration range of the test compound (i.e., the concentration of the test compound that achieves half-maximal inhibition of symptoms). Such information can be used to more accurately determine useful doses in humans. For example, plasma levels can be measured by high performance liquid chromatography.

[0071] Materials and methods

[0072] It should be understood that the examples and embodiments described herein are for illustrative purposes only. And those skilled in the art can think of various modifications or changes based on these embodiments and implementations, so these modifications or changes will be included in the spirit and scope of the present application and the scope of the appended claims. In addition, any element or limitation of any invention or its implementation disclosed herein can be combined with any and / or all other elements or limitations disclosed herein (alone or in any combination) or any other invention or its implementation, and all such combinations are included in the scope of the present invention, but are not limited thereto.

[0073] Intravitreal injection and optic nerve injury were performed according to the following protocol. Mice were anesthetized with a mixture of ketamine (80 mg / kg) and xylazine (10 mg / kg). The conjunctiva was exposed by clamping the eyelids with hemostats. Two microliters of vitreous were withdrawn using a Hamilton syringe, and 2 μL of AAV2-hSyn-GFP or AAV2-hSyn-Nrf2 was slowly injected into the vitreous. Four weeks after AAV injection, the optic nerve was exposed and then the optic nerve was injected with Dumont The optic nerve was squeezed for two seconds with forceps (Dumont #5 and Dumont #2; Fine Science Tools) to ensure complete optic nerve injury. 12 days after injury, 2 μL of CTB (1 mg / mL, Invitrogen) was injected into the eye to label regenerating axons.

[0074] Edaravone was administered intraperitoneally daily immediately after optic nerve injury.

[0075] Primary culture and re-seeding culture of DRG neurons were performed according to the following protocol. L3-L5 dorsal root ganglia (DRG) of adult wild-type mice were dissected out and digested in 0.5% collagenase for 90 minutes. Subsequently, the digestion medium was replaced with culture medium (Neurobase-A supplemented with penicillin-streptomycin and B-27). The digested DRG was then pipetted 20 to 30 times to isolate the DRG neurons. The isolated DRG neurons were seeded into 6-well plates pre-coated with poly-D-lysine and laminin. Primary cultured DRG neurons were subjected to 1 μM edaravone, 10 μM edaravone, or dimethyl sulfoxide (DMSO) Vehicle treatment for one day. Then, under continued treatment with vehicle / edaravone, neurons were resuspended and reseeded to another culture dish. After 20 hours, the reseeded culture was terminated with 4% paraformaldehyde solution (PFA). Tuj 1 staining was performed to observe DRG cell bodies and neurites.

[0076] All patents, patent applications, provisional applications, and publications referenced or cited herein are hereby incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

[0077] The following are examples of methods for implementing the present application. These examples should not be construed as Unless otherwise indicated, all percentages are by weight and all solvent mixing ratios are by volume.

[0078] Example 1—Nrf2 overexpression promotes optic nerve regeneration.

[0079] Adult wild-type mice were transfected with AAV2-hSyn-GFP or Nrf2 Intravitreal injection of adeno-associated virus (AAV) containing (AAV2-hSyn-Nrf2) was performed to overexpress GFP in the control group and Nrf2 in the experimental group. Four weeks after viral injection, optic nerve crush injury was performed. Axon regeneration effects were analyzed two weeks after injury. Unlike the control group, which showed negligible axon regeneration, Nrf2 overexpression significantly promoted axon regeneration ( Figure 1A and Figure 1B ).

[0080] Example 2 - Nrf2 overexpression enhances RGC survival.

[0081] Neuronal survival in neurological trauma or disease is essential for functional recovery. To investigate the neuroprotective effect of Nrf2, we also collected retinas two weeks after injury. Whole-tissue Tuj1 staining showed that Nrf2 overexpression significantly enhanced RGC survival ( Figure 2A and Figure 2B ).

[0082] Example 3 - Edaravone shows axonal growth promoting effect in DRG re-plating.

[0083] Adult mouse dorsal root ganglion (DRG) neurons were re-cultured to study Effect of Edaravone on axon growth. Primary cultured DRG neurons were treated with 1 μM Edaravone, 10 μM Edaravone or DMSO vehicle for one day. Then, under continued treatment with vehicle / Edaravone, the neurons were resuspended and re-seeded into another culture dish. The re-seeded culture continued for 20 hours for neurite growth. Compared with the vehicle control group, both 1 μM Edaravone and 10 μM Edaravone treatments showed significant axon growth promoting effects ( Figure 3A and Figure 3B ).

[0084] Example 4 - Daily treatment with edaravone increases RGC survival after optic nerve injury.

[0085] To evaluate the neuroprotective effect of edaravone, the optic nerve crush model was used. Adult mice were subjected to optic nerve crush and were administered vehicle or different doses of edaravone by intraperitoneal injection. The drugs were administered daily for two weeks, and then the retinas were collected. In addition, borneol was also administered to enhance the permeability of the blood-brain barrier. Whole-tissue Tuj 1 staining showed that daily injection of edaravone / borneol increased RGC survival after optic nerve injury ( Figure 4A and Figure 4B ).

[0086] Exemplary embodiments

[0087] Embodiment 1. A method for promoting axonal regeneration in a subject, the method comprising inducing Nrf2 activation.

[0088] Embodiment 2. The method according to embodiment 1 further comprises administering to the subject a therapeutically effective amount of edaravone, thereby inducing Nrf2 activation.

[0089] Embodiment 3. The method according to embodiment 2, wherein the subject is a mammal.

[0090] Embodiment 4. The method according to embodiment 3, wherein the subject is a human.

[0091] Embodiment 5. The method of embodiment 2, wherein edaravone enhances neuronal survival and promotes axonal growth in the subject.

[0092] Embodiment 6. The method according to embodiment 2, wherein edaravone is administered locally by intravitreal injection, intracranial injection, intradiscal injection, or administered intravenously or intraperitoneally.

[0093] Embodiment 7. The method of embodiment 1, wherein the subject suffers from spinal cord injury, traumatic brain injury, optic neuropathy, stroke, or glaucoma.

[0094] Embodiment 8. The method according to embodiment 1, wherein Nrf2 activation is induced by AAV-mediated Nrf2 overexpression or by an Nrf2 activator.

[0095] Embodiment 9. The method of embodiment 2, wherein administration of edaravone to the subject upregulates Nrf2, and wherein upregulation of Nrf2 reduces reactive oxygen species (ROS) The production of.

[0096] Embodiment 10. The method according to embodiment 1, wherein Nrf2 binds to the antioxidant response element (AR) site.

[0097] Embodiment 11. The method according to embodiment 2, wherein the dosage is about 0.1 mg / kg Edaravone was administered at a dose of about 100 mg / kg.

[0098] Embodiment 12. A method of treating a subject suffering from central nervous system (CNS) damage via Nrf2 activation, the method comprising administering to a subject in need thereof a therapeutically effective amount of edaravone, wherein Nrf2 activation is induced by edaravone.

[0099] Embodiment 13. The method of embodiment 12, wherein the subject is a mammal.

[0100] Embodiment 14. The method according to embodiment 12, wherein the subject is a human.

[0101] Embodiment 15. The method of embodiment 12, wherein administration of edaravone enhances neuronal survival and promotes axonal growth in a subject suffering from CNS injury.

[0102] Embodiment 16. The method of embodiment 12, wherein edaravone is administered by intravitreal injection, intracranial injection, intradiscal injection, intravenous injection, or intraperitoneal injection.

[0103] Embodiment 17. The method of embodiment 12, wherein administration of edaravone to the subject upregulates Nrf2, and wherein upregulation of Nrf2 reduces reactive oxygen species (ROS) The production of.

[0104] Embodiment 18. The method of embodiment 12, wherein Nrf2 binds to an antioxidant response element (AR) site.

[0105] Embodiment 19. The method according to embodiment 2, wherein the dosage is about 0.1 mg / kg Edaravone was administered at a dose of about 100 mg / kg.

[0106] Embodiment 20. The method according to embodiment 12, wherein the concentration of about 0.1 μg / mL Edaravone is administered in the composition at a concentration of about 10 mg / mL.

Claims

1. Use of a therapeutically effective amount of edaravone in the preparation of a drug for inducing Nrf2 activation, thereby promoting axonal regeneration in a subject.

2. The use according to claim 1, wherein the subject is a mammal.

3. The use according to claim 1, wherein the subject is a human.

4. The use according to claim 1, wherein edaravone enhances neuronal survival and promotes axonal growth in the subject.

5. The use according to claim 1, wherein edaravone is administered locally by intravitreal injection, intracranial injection, intradiscal injection, or by intravenous injection or intraperitoneal injection.

6. The use according to claim 1, wherein the subject suffers from spinal cord injury, traumatic brain injury, optic neuropathy, stroke or glaucoma.

7. The use according to claim 1, wherein Nrf2 activation is induced by AAV-mediated Nrf2 overexpression or by an Nrf2 activator.

8. The use according to claim 1, wherein administration of edaravone to the subject upregulates Nrf2, and wherein upregulation of Nrf2 reduces the generation of reactive oxygen species (ROS).

9. The use according to claim 1, wherein Nrf2 binds to the antioxidant response element (AR) site.

10. The use according to claim 1, wherein edaravone is administered at a dose of about 0.1 mg / kg to about 100 mg / kg.

11. Use of edaravone in the preparation of a medicament for treating a subject with central nervous system (CNS) damage by inducing Nrf2 activation.

12. The use according to claim 11, wherein the subject is a mammal.

13. The use according to claim 11, wherein the subject is a human.

14. The use according to claim 11, wherein administration of edaravone enhances neuronal survival and promotes axonal growth in a subject with CNS injury.

15. The use according to claim 11, wherein edaravone is administered locally by intravitreal injection, intracranial injection, intradiscal injection, or administered by intravenous injection or intraperitoneal injection.

16. The use according to claim 11, wherein administration of edaravone to the subject upregulates Nrf2, and wherein upregulation of Nrf2 reduces the generation of reactive oxygen species (ROS).

17. The use according to claim 11, wherein Nrf2 binds to the antioxidant response element (AR) site.

18. The use according to claim 11, wherein edaravone is administered at a dose of about 0.1 mg / kg to about 100 mg / kg.

19. The use according to claim 11, wherein the concentration of edaravone in the medicament is about 0.1 μg / mL to about 10 mg / mL.

Citation Information

Cited By

  • Application of edaravone in preparation of medicine for inhibiting senescence of vascular endothelial cells

    CN119606956A